Tandem Diabetes Care/$TNDM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ticker
$TNDM
Sector
Primary listing
Employees
2,650
Headquarters
Website
TNDM Metrics
BasicAdvanced
$1B
-
-$3.10
1.47
-
Price and volume
Market cap
$1B
Beta
1.47
52-week high
$38.88
52-week low
$9.98
Average daily volume
1.8M
Financial strength
Current ratio
2.443
Quick ratio
1.763
Long term debt to equity
325.638
Total debt to equity
340.56
Interest coverage (TTM)
-12.42%
Profitability
EBITDA (TTM)
-75.894
Gross margin (TTM)
52.55%
Net profit margin (TTM)
-20.51%
Operating margin (TTM)
-9.29%
Effective tax rate (TTM)
-1.50%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-6.41%
Return on equity (TTM)
-111.91%
Valuation
Price to revenue (TTM)
1.014
Price to book
7.77
Price to tangible book (TTM)
7.77
Price to free cash flow (TTM)
-19.837
Free cash flow yield (TTM)
-5.04%
Free cash flow per share (TTM)
-0.773
Growth
Revenue change (TTM)
25.84%
Earnings per share change (TTM)
48.18%
3-year revenue growth (CAGR)
9.37%
10-year revenue growth (CAGR)
32.64%
3-year earnings per share growth (CAGR)
145.37%
10-year earnings per share growth (CAGR)
-20.53%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Bulls say / Bears say
GAAP net loss widened to $52.4 million in Q2 2025 compared to $30.8 million a year earlier, highlighting ongoing profitability challenges despite revenue growth (Reuters)
Full-year 2025 revenue guidance of $997 million to $1.007 billion was below the consensus estimate of about $1.01 billion, prompting a 13.6% decline in after-hours trading and suggesting limited stock upside (Reuters)
TNDM shares dropped 18.7% in the June quarter and are down 57.9% year-to-date, reflecting investor concerns over the company’s high valuation and financial results (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
TNDM News
AllArticlesVideos
Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025
Business Wire7 days ago
Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States
Business Wire1 week ago
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tandem Diabetes Care stock?
Tandem Diabetes Care (TNDM) has a market cap of $1B as of October 09, 2025.
What is the P/E ratio for Tandem Diabetes Care stock?
The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of October 09, 2025.
Does Tandem Diabetes Care stock pay dividends?
No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of October 09, 2025.
When is the next Tandem Diabetes Care dividend payment date?
Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.